Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROR1 | Q01973 | 6/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 13/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.55 |
| ▸ | MLNR | O43193 | 1/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | YES1 | P07947 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589881 | 0.91 | CSF1R (0.67) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL29506341 | 0.91 | CSF1R (0.67) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL22243490 | 0.90 | CSF1R (0.66) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL29493472 | 0.90 | CSF1R (0.66) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL22580709 | 0.89 | CSF1R (0.61) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL30010219 | 0.88 | CSF1R (0.72) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL15088585 | 0.87 | CSF1R (0.62) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL19317721 | 0.84 | ROR1 (0.79) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL24123162 | 0.84 | ABL1 (0.66) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL17471717 | 0.83 | CSF1R (0.57) | ROR1CSF1RABL1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725452-B2 | Substituted indoles and pyrroles as RIP kinase inhibitors | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-20140323489-A1 | HYBRID NECROPTOSIS INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-30 | — | — | US | disclosed |
| US-20130178622-A1 | Methods and Compositions for Treating Cancer | ARIAD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323489-A1 | HYBRID NECROPTOSIS INHIBITORS | RIPK3, RIPK1, RIPK4 | ROR1 1517/4885CSF1R 1248/4885ABL1 1547/4885 |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | RIPK3, RIPK1, RIPK4 | ROR1 1517/4885CSF1R 1248/4885ABL1 1547/4885 |
| US-20130178622-A1 | Methods and Compositions for Treating Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MKI67 | ROR1 4639/4885CSF1R 4566/4885ABL1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.